ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.52
-0.22%
US Tech 100
17,723.20
0.00%
S&P 500
5,221.42
-0.02%
US Dollar vs CAD
1.36787
0.09%
Bitcoin
61,862.68
-1.66%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Lantern Pharma Inc (LTRN)

  7. Lantern Pharma Inc (LTRN) News

LTRN

Lantern Pharma (LTRN)

Lantern Pharma Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LTRN
DateTimeSourceHeadlineSymbolCompany
05/13/202412:30AMBusiness WireOregon Therapeutics et Lantern Pharma lancent une collaboration stratégique dans le domaine de l’intelligence artificielle pour optimiser le développement du XCE853, premier candidat médicament de sa catégorie, un puissant inhibiteur...NASDAQ:LTRNLantern Pharma Inc
05/09/20243:05PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LTRNLantern Pharma Inc
05/09/20243:02PMBusiness WireLantern Pharma Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:LTRNLantern Pharma Inc
05/06/20242:00AMBusiness WireOregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer MetabolismNASDAQ:LTRNLantern Pharma Inc
05/02/20246:30AMBusiness WireLantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ETNASDAQ:LTRNLantern Pharma Inc
04/24/20247:00AMBusiness WireLantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug DevelopmentNASDAQ:LTRNLantern Pharma Inc
04/22/20247:12AMBusiness WireLantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and TaiwanNASDAQ:LTRNLantern Pharma Inc
03/18/20243:02PMBusiness WireLantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business HighlightsNASDAQ:LTRNLantern Pharma Inc
03/18/20246:12AMIH Market NewsAnticipation Builds on Wall Street for Federal Reserve’s Upcoming Policy Moves; WTI and Brent See UpticksNASDAQ:LTRNLantern Pharma Inc
03/15/20247:00AMBusiness WireLantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284NASDAQ:LTRNLantern Pharma Inc
03/11/20246:30AMBusiness WireLantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ETNASDAQ:LTRNLantern Pharma Inc
03/05/20247:01AMBusiness WireLantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual ConferenceNASDAQ:LTRNLantern Pharma Inc
03/04/20247:01AMBusiness WireLantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development TimelinesNASDAQ:LTRNLantern Pharma Inc
02/29/20248:54PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LTRNLantern Pharma Inc
02/15/20247:01AMBusiness WireLantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor CancersNASDAQ:LTRNLantern Pharma Inc
01/19/20243:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LTRNLantern Pharma Inc
01/17/20246:30AMBusiness WireStarlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical OfficerNASDAQ:LTRNLantern Pharma Inc
12/29/20233:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LTRNLantern Pharma Inc
12/01/20235:02AMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:LTRNLantern Pharma Inc
12/01/20235:00AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LTRNLantern Pharma Inc
11/30/20237:00AMBusiness WireFDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)NASDAQ:LTRNLantern Pharma Inc
11/24/20233:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LTRNLantern Pharma Inc
11/08/20233:05PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LTRNLantern Pharma Inc
11/08/20233:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LTRNLantern Pharma Inc
11/08/20233:01PMBusiness WireLantern Pharma Reports Third Quarter 2023 Financial Results and Operational HighlightsNASDAQ:LTRNLantern Pharma Inc
11/01/20237:00AMBusiness WireLantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ETNASDAQ:LTRNLantern Pharma Inc
10/20/20234:25PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LTRNLantern Pharma Inc
10/10/20237:00AMBusiness WireLantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ETNASDAQ:LTRNLantern Pharma Inc
10/03/20237:00AMBusiness WireLantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in GlioblastomaNASDAQ:LTRNLantern Pharma Inc
09/25/20237:30AMBusiness WireLantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid TumorsNASDAQ:LTRNLantern Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:LTRN

Your Recent History

NYSE
GME
GameStop
NYSE
AMC
AMC Entertainment
USOTC
ASKH
Astika (PK)
USOTC
IGPK
Intergrated Cannabis Sol... (PK)
USOTC
NSAV
Net Savings Link (PK)
USOTC
EPAZ
Epazz (PK)
USOTC
VDRM
ViaDerma (PK)
USOTC
VPLM
Voip Pal Com (QB)
USOTC
XCRT
Xcelerate (QB)
COIN
BTCUSD
Bitcoin
USOTC
HMBL
HUMBL (PK)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
IFUS
Impact Fusion (PK)
NASDAQ
PLUG
Plug Power
NASDAQ
RNAZ
TransCode Therapeutics
USOTC
MCIC
Multicorp (PK)
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved